No Data
No Data
OptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach Patients
WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare
OptimizeRx (NASDAQ:OPRX) Shareholders Have Endured a 83% Loss From Investing in the Stock Three Years Ago
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
7 analysts have shared their evaluations of OptimizeRx (NASDAQ:OPRX) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates their recent
Express News | JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
JMP Securities Maintains OptimizeRx(OPRX.US) With Buy Rating, Maintains Target Price $16
JMP Securities analyst Constantine Davides maintains $OptimizeRx(OPRX.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 23.6%
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing